Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 24, Issue 7, Pages 727-730
Publisher
Informa Healthcare
Online
2014-05-30
DOI
10.1517/13543776.2014.915945
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)
- (2014) Raghava R Kethiri et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle
- (2013) Evy Lobbestael et al. BIOCHEMICAL JOURNAL
- Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
- (2013) Marco A. S. Baptista et al. PLoS One
- (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD
- (2012) C-Y Chen et al. CELL DEATH AND DIFFERENTIATION
- Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
- (2012) Renee Vancraenenbroeck et al. CNS & Neurological Disorders-Drug Targets
- Axon degeneration in Parkinson's disease
- (2012) Robert E. Burke et al. EXPERIMENTAL NEUROLOGY
- Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)
- (2012) Xianming Deng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
- (2011) Martin C. Herzig et al. HUMAN MOLECULAR GENETICS
- A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2
- (2011) J. Dusonchet et al. JOURNAL OF NEUROSCIENCE
- On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies
- (2011) V. Daniëls et al. NEUROSIGNALS
- What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
- (2011) Olga Corti et al. PHYSIOLOGICAL REVIEWS
- Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
- (2011) David Ramonet et al. PLoS One
- Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
- (2010) Nicolas Dzamko et al. BIOCHEMICAL JOURNAL
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
- (2010) Byoung Dae Lee et al. NATURE MEDICINE
- The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
- (2010) Mark R. Cookson NATURE REVIEWS NEUROSCIENCE
- Molecular pathogenesis of Parkinson disease: insights from genetic studies
- (2009) Thomas Gasser EXPERT REVIEWS IN MOLECULAR MEDICINE
- Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
- (2009) Wataru Satake et al. NATURE GENETICS
- Genome-wide association study reveals genetic risk underlying Parkinson's disease
- (2009) Javier Simón-Sánchez et al. NATURE GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search